Market Overview

UPDATE: JP Morgan Upgrades Thermo Fisher Scientific to Overweight on Favorable Risk/Reward

Related TMO
Benzinga's M&A Chatter for Monday, October 17, 2016
Benzinga's Top Initiations

JP Morgan upgraded Thermo Fisher Scientific (NYSE: TMO) from Neutral to Overweight and raised the price target from $70.00 to $80.00.

JP Morgan noted, "We are upgrading Thermo Fisher Scientific (TMO) from Neutral to Overweight on favorable risk/reward due to conservative guidance that should be at worst achievable, and more likely beatable, and an improving record of capital deployment since management has increasingly focused on the higher bar of ROIC, rather than simply adjusted EPS accretion. The company's robust and growing free cash flow provides clear optionality around additional capital deployment, including but not limited to recent press reports (Reuters) that it is now evaluating a purchase of Life Technologies (LIFE)."

Thermo Fisher Scientific closed at $72.14 on Thursday.

Latest Ratings for TMO

Sep 2016JP MorganAssumesOverweight
Sep 2016UBSMaintainsBuy
Sep 2016Cleveland ResearchDowngradesBuyNeutral

View More Analyst Ratings for TMO
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Analyst Ratings


Related Articles (TMO)

View Comments and Join the Discussion!